Dr. Roee Atlas
Prior to his current position as the CEO of MedTech, Dr. Atlas headed the National Institute for Biotechnology in the Negev Ltd. (NIBN), an incubator at Ben-Gurion University in the Negev. The incubator’s activities focused on pre-clinical development of pharmaceutical and biopharmaceutical drugs for indications such as cancer, autoimmunity, neurodegeneration, metabolism, and more. At NIBN, Dr. Atlas gained experience in advancing pre-clinical development programs for small molecules and biopharmaceuticals. In addition, he led the Intellectual Property and business aspects of the Incubator. Prior to that role, Dr. Atlas served as CEO of a biotech startup company in the field of pain management for dentistry applications. Before that, he was a project manager at Omrix Biopharmaceuticals (a J&J company), in charge of pre-clinical development of tissue regeneration applications for Omrix's Fibrin technology.
Dr. Atlas studied molecular biology and completed a Ph.D. degree at the Weizmann Institute of Science in 2005, followed by a postdoc at Columbia University Medical School, New York.
Ms. Shmuel is the assistant to the CEO at Rambam MedTech. She is responsible for promoting innovation among the Rambam Health Care Campus staff; organizing conferences and seminars, managing the hospital’s patent portfolio, and establishing contacts with contract research organizations. Ms. Shmuel has eight years of experience managing departments in large companies and law firms. She completed her LL.M at the University of Haifa
Ronen Kahana is the director of business development at Rambam MedTech. Prior to that role, he founded and headed a unique pharmaceutical startup company that developed novel drugs for endogenous recovery of bone marrow and blood parameters. In the past, he innovated novel anti-viral applications, co-founded a biotech startup company centered on anti-viral management in humans and animals, and worked at the Kimron Veterinary Institute in the field of vaccine control, where he developed and implemented new technologies and established Crucell’s PER.C6® technology. Mr. Kahana holds an M.Sc. in industrial biotechnology from Bar-Ilan University.